GlassScriptPhysician profile
Laura Mathis
NPI 1841666583
$6,679.00
in general payments reported to CMS, 2019-2025
37 companies · $2,590 in 2025
The $2,590 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $132 · 2023: $527 · 2024: $3,313 · 2025: $2,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,090 · Travel and Lodging: $1,169 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,089.75 |
| Travel and Lodging | $1,168.98 |
| Education | $171.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,704.69 | 2021-2024 | Axonics, Bulkamid |
| Janssen Biotech, INC. | $653.17 | 2022-2025 | Erleada, Akeega |
| Pfizer INC. | $567.80 | 2023-2025 | |
| Urogen Pharma, INC. | $451.75 | 2023-2025 | Jelmyto |
| Bayer Healthcare Pharmaceuticals INC. | $366.69 | 2023-2025 | |
| Teleflex LLC | $343.55 | 2024-2025 | Barrigel, Urolift |
| Dendreon Pharmaceuticals LLC | $319.53 | 2024-2025 | Provenge |
| Astellas Pharma US INC | $319.37 | 2023-2025 | Xtandi, Myrbetriq |
| Myriad Genetic Laboratories, INC. | $307.30 | 2023-2025 | Prolaris |
| Sumitomo Pharma America, INC. | $238.62 | 2024-2025 | Gemtesa, Orgovyx |
| Boston Scientific Corporation | $205.02 | 2023-2025 | Solyx Sis System, Lumenis Pulse 120h |
| Abbvie INC. | $187.45 | 2024-2025 | |
| Tempus Ai, INC | $167.45 | 2024 | Xt Cdx |
| Blue Earth Diagnostics | $94.34 | 2023-2024 | |
| C. R. Bard, INC. & Subsidiaries | $85.59 | 2025 | Purewick Female External Catheter, Bard Urinary Drainage Bag |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $73.03 | 2025 | |
| Photocure INC | $73.00 | 2024-2025 | Cysview |
| Novo Nordisk INC | $58.36 | 2022-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $48.25 | 2024 | |
| Ferring Pharmaceuticals INC. | $45.36 | 2024 | Adstiladrin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.45 | 2022 | |
| Telix Pharmaceuticals | $31.24 | 2025 | Illuccix |
| Baxter Healthcare | $29.80 | 2024 | Perclot |
| Immunitybio, INC. | $28.23 | 2025 | |
| Verity Pharmaceuticals INC. | $24.69 | 2024 | Trelstar |
| Coloplast Corp | $23.85 | 2024 | |
| Progenics Pharmaceuticals, INC. | $22.25 | 2023 | Pylarify |
| Kowa Pharmaceuticals America, INC. | $21.60 | 2023 | Seglentis |
| Genentech USA, INC. | $21.16 | 2021 | |
| Accord Healthcare, INC. | $19.26 | 2024 | |
| Endo USA, INC. | $19.21 | 2024 | Xiaflex |
| Theratechnologies INC. | $17.88 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.60 | 2022 | |
| Daiichi Sankyo INC. | $17.08 | 2023 | Injectafer |
| Lilly USA, LLC | $15.03 | 2023 | Mounjaro |
| Glaxosmithkline, LLC. | $13.71 | 2022 | |
| Medtronic, INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.